<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289899</url>
  </required_header>
  <id_info>
    <org_study_id>2290/9</org_study_id>
    <nct_id>NCT01289899</nct_id>
  </id_info>
  <brief_title>Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects</brief_title>
  <official_title>BR-A-657, A Phase 1, Double-blind, Placebo-controlled, Ascending Multiple Oral Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety and tolerability and to determine the
      Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BR-A-657 120, 360, or placebo were administered once daily for 7days to 16 healthy male
      subjects.

      Pharmacokinetic and Pharmacodynamic(PK/PD) parameters were monitored at pre-specified times
      from each subjects.

      PK parameters: Area Under the Curve(AUC), Cmax, half-life, etc. PD parameters: Aldosterone,
      Plasma renin activity, Angiotensin I, Angiotensin II Adverse events are reported.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No of subjects with Adverse events(AE) from each observations</measure>
    <time_frame>up to 5~7days post final(7th) dose</time_frame>
    <description>AE reporting: Day 1: Predose, 3 &amp; 12h, Days 2~7: Predose, Days 8,9: Once daily, 5~7days post final dose
Vital signs: Day 1: Predose, 0.5,1,2,4,8,12,24h,Days 3~6: Predose Day 7: Predose, 0.5,1,2,4,8,12,24,48h, 5~7days post final dose
ECG: Days 1 &amp; 7: Predose, 2, 4, 8 &amp; 24h, Day 4: Predose, 5~7days post final dose
Laboratory examination: Days 1 &amp; 4: Predose, Day 7: Predose &amp; 24h, 5~7days post final dose
Physical examination: predose, 5~7days post final dose
Body weight: predose, Days 4 &amp; 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC)</measure>
    <time_frame>predose,0.5,1,1.5,2,3,4,6,8,12,16,24,(48)h on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax).</measure>
    <time_frame>predose,0.5,1,1.5,2,3,4,6,8,12,16,24,(48)h on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parent plasma terminal elimination half life (tÂ½)</measure>
    <time_frame>predose,0.5,1,1.5,2,3,4,6,8,12,16,24,(48)h on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total plasma clearance (CL/F)</measure>
    <time_frame>predose,0.5,1,1.5,2,3,4,6,8,12,16,24,(48)h on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA)</measure>
    <time_frame>predose,0.5,1,1.5,2,3,4,6,8,12,16,24,(48)h on day 1 and day 7</time_frame>
    <description>RA1=Accumulation ratio based on AUCinf
RA2=Accumulation ratio based on Cmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BR-A-657 120mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BR-A-657 360mg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR-A-657</intervention_name>
    <description>120, 360mg or placebo 7days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Fimasartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male of 18-55 years old

          -  BMI 19-29kg/m2

          -  subjects in good health

          -  subjects with written informed consent

        Exclusion Criteria:

          -  subjects with multiple drug allergy or allergy to ARB

          -  subjects with medication that affect drug absorption or elimination within 30days.

          -  subjects with orthostatic hypotension of &gt;20mmHg decrease of sbp

          -  subjects with history of neurologic, liver, renal, GI, CV, psychological or other
             major disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Engmann, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>February 3, 2011</last_update_submitted>
  <last_update_submitted_qc>February 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paik, Assistant manager</name_title>
    <organization>Boryung Pharm. Co., Ltd</organization>
  </responsible_party>
  <keyword>BR-A-657</keyword>
  <keyword>Fimasartan</keyword>
  <keyword>multiple-dose</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

